Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.

The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the “relatively small benefit” it provides does not outweigh its cost.1 The draft guidelines,